These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 22580530

  • 1. Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.
    Dhanesha N, Joharapurkar A, Shah G, Dhote V, Kshirsagar S, Bahekar R, Jain M.
    Pharmacol Rep; 2012; 64(1):140-9. PubMed ID: 22580530
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
    Dhanesha N, Joharapurkar A, Shah G, Dhote V, Kshirsagar S, Bahekar R, Jain M.
    J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
    Ding X, Saxena NK, Lin S, Gupta NA, Anania FA.
    Hepatology; 2006 Jan; 43(1):173-81. PubMed ID: 16374859
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
    Luque MA, González N, Márquez L, Acitores A, Redondo A, Morales M, Valverde I, Villanueva-Peñacarrillo ML.
    J Endocrinol; 2002 Jun; 173(3):465-73. PubMed ID: 12065236
    [Abstract] [Full Text] [Related]

  • 10. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
    Patel V, Joharapurkar A, Gandhi T, Patel K, Dhanesha N, Kshirsagar S, Dhote V, Detroja J, Bahekar R, Jain M.
    J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
    [Abstract] [Full Text] [Related]

  • 11. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice.
    Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Lee WY.
    PLoS One; 2012 Jun; 7(2):e31394. PubMed ID: 22363635
    [Abstract] [Full Text] [Related]

  • 12. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F, Fehmann HC, Göke R, Göke B.
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [Abstract] [Full Text] [Related]

  • 13. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R, Yano T, Ogawa J, Tanaka N, Toda N, Yoshida M, Takano R, Inoue M, Honda T, Kume S, Matsumoto K.
    Eur J Pharmacol; 2014 Aug 15; 737():194-201. PubMed ID: 24858371
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
    Zheng YC.
    Yao Xue Xue Bao; 2015 Dec 15; 50(12):1668-72. PubMed ID: 27169293
    [Abstract] [Full Text] [Related]

  • 17. Evidence for paracrine/autocrine regulation of GLP-1-producing cells.
    Kappe C, Zhang Q, Holst JJ, Nyström T, Sjöholm A.
    Am J Physiol Cell Physiol; 2013 Nov 15; 305(10):C1041-9. PubMed ID: 23986202
    [Abstract] [Full Text] [Related]

  • 18. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM.
    Regul Pept; 2007 Jun 07; 141(1-3):113-9. PubMed ID: 17292977
    [Abstract] [Full Text] [Related]

  • 19. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
    Claus TH, Pan CQ, Buxton JM, Yang L, Reynolds JC, Barucci N, Burns M, Ortiz AA, Roczniak S, Livingston JN, Clairmont KB, Whelan JP.
    J Endocrinol; 2007 Feb 07; 192(2):371-80. PubMed ID: 17283237
    [Abstract] [Full Text] [Related]

  • 20. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.
    Breast Cancer Res Treat; 2012 Apr 07; 132(2):449-61. PubMed ID: 21638053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.